Header

UZH-Logo

Maintenance Infos

Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring


Cerciello, Ferdinando; Choi, Meena; Nicastri, Annalisa; Bausch-Fluck, Damaris; Ziegler, Annemarie; Vitek, Olga; Felley-Bosco, Emanuela; Stahel, Rolf; Aebersold, Ruedi; Wollscheid, Bernd (2013). Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clinical Proteomics, 10:16.

Abstract

BACKGROUND Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM). However, the evaluation of potential new serum biomarker candidates is hampered by a lack of assay technologies for their clinical evaluation. Here we followed a hypothesis-driven targeted proteomics strategy for the identification and clinical evaluation of MPM candidate biomarkers in serum of patient cohorts. RESULTS Based on the hypothesis that cell surface exposed glycoproteins are prone to be released from tumor-cells to the circulatory system, we screened the surfaceome of model cell lines for potential MPM candidate biomarkers. Selected Reaction Monitoring (SRM) assay technology allowed for the direct evaluation of the newly identified candidates in serum. Our evaluation of 51 candidate biomarkers in the context of a training and an independent validation set revealed a reproducible glycopeptide signature of MPM in serum which complemented the MPM biomarker mesothelin. CONCLUSIONS Our study shows that SRM assay technology enables the direct clinical evaluation of protein-derived candidate biomarker panels for which clinically reliable ELISA's currently do not exist.

Abstract

BACKGROUND Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM). However, the evaluation of potential new serum biomarker candidates is hampered by a lack of assay technologies for their clinical evaluation. Here we followed a hypothesis-driven targeted proteomics strategy for the identification and clinical evaluation of MPM candidate biomarkers in serum of patient cohorts. RESULTS Based on the hypothesis that cell surface exposed glycoproteins are prone to be released from tumor-cells to the circulatory system, we screened the surfaceome of model cell lines for potential MPM candidate biomarkers. Selected Reaction Monitoring (SRM) assay technology allowed for the direct evaluation of the newly identified candidates in serum. Our evaluation of 51 candidate biomarkers in the context of a training and an independent validation set revealed a reproducible glycopeptide signature of MPM in serum which complemented the MPM biomarker mesothelin. CONCLUSIONS Our study shows that SRM assay technology enables the direct clinical evaluation of protein-derived candidate biomarker panels for which clinically reliable ELISA's currently do not exist.

Statistics

Citations

28 citations in Web of Science®
29 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

22 downloads since deposited on 17 Jul 2014
9 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, not refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:17 Jul 2014 12:50
Last Modified:08 Dec 2017 06:29
Publisher:BioMed Central
ISSN:1542-6416
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1186/1559-0275-10-16
PubMed ID:24207061

Download

Download PDF  'Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring'.
Preview
Content: Published Version
Filetype: PDF
Size: 1MB
View at publisher
Licence: Creative Commons: Attribution 2.0 Generic (CC BY 2.0)